A controlled trial of remacemide hydrochloride in Huntington's disease
Identifieur interne : 002F54 ( Istex/Corpus ); précédent : 002F53; suivant : 002F55A controlled trial of remacemide hydrochloride in Huntington's disease
Auteurs : Kieburtz ; Andrew Feigin ; Michael Mcdermott ; Peter Como ; David Abwender ; Carol Zimmerman ; Charlyne Hickey ; Constance Orme ; Kathy Claude ; Jennie Sotack ; J. Timothy Greenamyre ; Cynthia Dunn ; Ira ShoulsonSource :
- Movement Disorders [ 0885-3185 ] ; 1996-05.
English descriptors
Abstract
We conducted a randomized, double‐blind, placebo‐controlled tolerability study of a N‐methyl‐D‐aspartate (NMDA) glutamate receptor ion‐channel blocker, remacemide hydrochloride, in 31 independently ambulatory patients (18 men, 13 women) with Huntington's disease (HD). Subjects were randomized to receive either placebo or active remacemide at dosages of 200 mg/day or 600 mg/day. The primary outcome measure was the proportion of subjects able to compleate the study with the assigned treatment. Remacemide was generally well tolerated, and no significant differences between the treatment arms were found in the primary outcome measure. A trend toward impovement in chorea was observed among subjects administered remacemide 200 mg/day. Based on the tolerability and safety demonstrated during this short‐trem trial, remacemide warrants more extended controlled investigation in patients with HD.
Url:
DOI: 10.1002/mds.870110310
Links to Exploration step
ISTEX:7D61E5BF3D4506BB687D09C22412B15C5159C9E0Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A controlled trial of remacemide hydrochloride in Huntington's disease</title><author><name sortKey="Kieburtz" sort="Kieburtz" uniqKey="Kieburtz" last="Kieburtz">Kieburtz</name><affiliation><mods:affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Feigin, Andrew" sort="Feigin, Andrew" uniqKey="Feigin A" first="Andrew" last="Feigin">Andrew Feigin</name><affiliation><mods:affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Mcdermott, Michael" sort="Mcdermott, Michael" uniqKey="Mcdermott M" first="Michael" last="Mcdermott">Michael Mcdermott</name><affiliation><mods:affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Como, Peter" sort="Como, Peter" uniqKey="Como P" first="Peter" last="Como">Peter Como</name><affiliation><mods:affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Abwender, David" sort="Abwender, David" uniqKey="Abwender D" first="David" last="Abwender">David Abwender</name><affiliation><mods:affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Zimmerman, Carol" sort="Zimmerman, Carol" uniqKey="Zimmerman C" first="Carol" last="Zimmerman">Carol Zimmerman</name><affiliation><mods:affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Hickey, Charlyne" sort="Hickey, Charlyne" uniqKey="Hickey C" first="Charlyne" last="Hickey">Charlyne Hickey</name><affiliation><mods:affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Orme, Constance" sort="Orme, Constance" uniqKey="Orme C" first="Constance" last="Orme">Constance Orme</name><affiliation><mods:affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Claude, Kathy" sort="Claude, Kathy" uniqKey="Claude K" first="Kathy" last="Claude">Kathy Claude</name><affiliation><mods:affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Sotack, Jennie" sort="Sotack, Jennie" uniqKey="Sotack J" first="Jennie" last="Sotack">Jennie Sotack</name><affiliation><mods:affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Greenamyre, J Timothy" sort="Greenamyre, J Timothy" uniqKey="Greenamyre J" first="J. Timothy" last="Greenamyre">J. Timothy Greenamyre</name><affiliation><mods:affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Dunn, Cynthia" sort="Dunn, Cynthia" uniqKey="Dunn C" first="Cynthia" last="Dunn">Cynthia Dunn</name><affiliation><mods:affiliation>Fisons Pharmaceuticals, Inc., Rochester, New York, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Shoulson, Ira" sort="Shoulson, Ira" uniqKey="Shoulson I" first="Ira" last="Shoulson">Ira Shoulson</name><affiliation><mods:affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:7D61E5BF3D4506BB687D09C22412B15C5159C9E0</idno><date when="1996" year="1996">1996</date><idno type="doi">10.1002/mds.870110310</idno><idno type="url">https://api.istex.fr/document/7D61E5BF3D4506BB687D09C22412B15C5159C9E0/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002F54</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">A controlled trial of remacemide hydrochloride in Huntington's disease</title><author><name sortKey="Kieburtz" sort="Kieburtz" uniqKey="Kieburtz" last="Kieburtz">Kieburtz</name><affiliation><mods:affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Feigin, Andrew" sort="Feigin, Andrew" uniqKey="Feigin A" first="Andrew" last="Feigin">Andrew Feigin</name><affiliation><mods:affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Mcdermott, Michael" sort="Mcdermott, Michael" uniqKey="Mcdermott M" first="Michael" last="Mcdermott">Michael Mcdermott</name><affiliation><mods:affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Como, Peter" sort="Como, Peter" uniqKey="Como P" first="Peter" last="Como">Peter Como</name><affiliation><mods:affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Abwender, David" sort="Abwender, David" uniqKey="Abwender D" first="David" last="Abwender">David Abwender</name><affiliation><mods:affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Zimmerman, Carol" sort="Zimmerman, Carol" uniqKey="Zimmerman C" first="Carol" last="Zimmerman">Carol Zimmerman</name><affiliation><mods:affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Hickey, Charlyne" sort="Hickey, Charlyne" uniqKey="Hickey C" first="Charlyne" last="Hickey">Charlyne Hickey</name><affiliation><mods:affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Orme, Constance" sort="Orme, Constance" uniqKey="Orme C" first="Constance" last="Orme">Constance Orme</name><affiliation><mods:affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Claude, Kathy" sort="Claude, Kathy" uniqKey="Claude K" first="Kathy" last="Claude">Kathy Claude</name><affiliation><mods:affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Sotack, Jennie" sort="Sotack, Jennie" uniqKey="Sotack J" first="Jennie" last="Sotack">Jennie Sotack</name><affiliation><mods:affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Greenamyre, J Timothy" sort="Greenamyre, J Timothy" uniqKey="Greenamyre J" first="J. Timothy" last="Greenamyre">J. Timothy Greenamyre</name><affiliation><mods:affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Dunn, Cynthia" sort="Dunn, Cynthia" uniqKey="Dunn C" first="Cynthia" last="Dunn">Cynthia Dunn</name><affiliation><mods:affiliation>Fisons Pharmaceuticals, Inc., Rochester, New York, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Shoulson, Ira" sort="Shoulson, Ira" uniqKey="Shoulson I" first="Ira" last="Shoulson">Ira Shoulson</name><affiliation><mods:affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1996-05">1996-05</date><biblScope unit="vol">11</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="273">273</biblScope><biblScope unit="page" to="277">277</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">7D61E5BF3D4506BB687D09C22412B15C5159C9E0</idno><idno type="DOI">10.1002/mds.870110310</idno><idno type="ArticleID">MDS870110310</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Clinical trial</term><term>Glutamate‐receptor blocker</term><term>Huntington's disease</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We conducted a randomized, double‐blind, placebo‐controlled tolerability study of a N‐methyl‐D‐aspartate (NMDA) glutamate receptor ion‐channel blocker, remacemide hydrochloride, in 31 independently ambulatory patients (18 men, 13 women) with Huntington's disease (HD). Subjects were randomized to receive either placebo or active remacemide at dosages of 200 mg/day or 600 mg/day. The primary outcome measure was the proportion of subjects able to compleate the study with the assigned treatment. Remacemide was generally well tolerated, and no significant differences between the treatment arms were found in the primary outcome measure. A trend toward impovement in chorea was observed among subjects administered remacemide 200 mg/day. Based on the tolerability and safety demonstrated during this short‐trem trial, remacemide warrants more extended controlled investigation in patients with HD.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Dr. Kieburtz</name><affiliations><json:string>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</json:string></affiliations></json:item><json:item><name>Andrew Feigin</name><affiliations><json:string>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</json:string></affiliations></json:item><json:item><name>Michael McDermott</name><affiliations><json:string>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</json:string></affiliations></json:item><json:item><name>Peter Como</name><affiliations><json:string>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</json:string></affiliations></json:item><json:item><name>David Abwender</name><affiliations><json:string>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</json:string></affiliations></json:item><json:item><name>Carol Zimmerman</name><affiliations><json:string>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</json:string></affiliations></json:item><json:item><name>Charlyne Hickey</name><affiliations><json:string>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</json:string></affiliations></json:item><json:item><name>Constance Orme</name><affiliations><json:string>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</json:string></affiliations></json:item><json:item><name>Kathy Claude</name><affiliations><json:string>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</json:string></affiliations></json:item><json:item><name>Jennie Sotack</name><affiliations><json:string>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</json:string></affiliations></json:item><json:item><name>J. Timothy Greenamyre</name><affiliations><json:string>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</json:string></affiliations></json:item><json:item><name>Cynthia Dunn</name><affiliations><json:string>Fisons Pharmaceuticals, Inc., Rochester, New York, U.S.A.</json:string></affiliations></json:item><json:item><name>Ira Shoulson</name><affiliations><json:string>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Huntington's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Clinical trial</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Glutamate‐receptor blocker</value></json:item></subject><language><json:string>eng</json:string></language><abstract>We conducted a randomized, double‐blind, placebo‐controlled tolerability study of a N‐methyl‐D‐aspartate (NMDA) glutamate receptor ion‐channel blocker, remacemide hydrochloride, in 31 independently ambulatory patients (18 men, 13 women) with Huntington's disease (HD). Subjects were randomized to receive either placebo or active remacemide at dosages of 200 mg/day or 600 mg/day. The primary outcome measure was the proportion of subjects able to compleate the study with the assigned treatment. Remacemide was generally well tolerated, and no significant differences between the treatment arms were found in the primary outcome measure. A trend toward impovement in chorea was observed among subjects administered remacemide 200 mg/day. Based on the tolerability and safety demonstrated during this short‐trem trial, remacemide warrants more extended controlled investigation in patients with HD.</abstract><qualityIndicators><score>4.051</score><pdfVersion>1.3</pdfVersion><pdfPageSize>576 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>898</abstractCharCount><pdfWordCount>2587</pdfWordCount><pdfCharCount>17178</pdfCharCount><pdfPageCount>5</pdfPageCount><abstractWordCount>122</abstractWordCount></qualityIndicators><title>A controlled trial of remacemide hydrochloride in Huntington's disease</title><genre><json:string>Serial article</json:string></genre><host><volume>11</volume><pages><total>5</total><last>277</last><first>273</first></pages><issn><json:string>0885-3185</json:string></issn><issue>3</issue><subject><json:item><value>Article</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>1996</publicationDate><copyrightDate>1996</copyrightDate><doi><json:string>10.1002/mds.870110310</json:string></doi><id>7D61E5BF3D4506BB687D09C22412B15C5159C9E0</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/7D61E5BF3D4506BB687D09C22412B15C5159C9E0/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/7D61E5BF3D4506BB687D09C22412B15C5159C9E0/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/7D61E5BF3D4506BB687D09C22412B15C5159C9E0/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">A controlled trial of remacemide hydrochloride in Huntington's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>1996</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">A controlled trial of remacemide hydrochloride in Huntington's disease</title><author><persName><surname>Kieburtz</surname><roleName type="degree">Dr.</roleName></persName><note type="correspondence"><p>Correspondence: University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, U.S.A.</p></note><affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</affiliation></author><author><persName><forename type="first">Andrew</forename><surname>Feigin</surname></persName><affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</affiliation></author><author><persName><forename type="first">Michael</forename><surname>McDermott</surname></persName><affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</affiliation></author><author><persName><forename type="first">Peter</forename><surname>Como</surname></persName><affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</affiliation></author><author><persName><forename type="first">David</forename><surname>Abwender</surname></persName><affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</affiliation></author><author><persName><forename type="first">Carol</forename><surname>Zimmerman</surname></persName><affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</affiliation></author><author><persName><forename type="first">Charlyne</forename><surname>Hickey</surname></persName><affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</affiliation></author><author><persName><forename type="first">Constance</forename><surname>Orme</surname></persName><affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</affiliation></author><author><persName><forename type="first">Kathy</forename><surname>Claude</surname></persName><affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</affiliation></author><author><persName><forename type="first">Jennie</forename><surname>Sotack</surname></persName><affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</affiliation></author><author><persName><forename type="first">J. Timothy</forename><surname>Greenamyre</surname></persName><affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</affiliation></author><author><persName><forename type="first">Cynthia</forename><surname>Dunn</surname></persName><affiliation>Fisons Pharmaceuticals, Inc., Rochester, New York, U.S.A.</affiliation></author><author><persName><forename type="first">Ira</forename><surname>Shoulson</surname></persName><affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1996-05"></date><biblScope unit="vol">11</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="273">273</biblScope><biblScope unit="page" to="277">277</biblScope></imprint></monogr><idno type="istex">7D61E5BF3D4506BB687D09C22412B15C5159C9E0</idno><idno type="DOI">10.1002/mds.870110310</idno><idno type="ArticleID">MDS870110310</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1996</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>We conducted a randomized, double‐blind, placebo‐controlled tolerability study of a N‐methyl‐D‐aspartate (NMDA) glutamate receptor ion‐channel blocker, remacemide hydrochloride, in 31 independently ambulatory patients (18 men, 13 women) with Huntington's disease (HD). Subjects were randomized to receive either placebo or active remacemide at dosages of 200 mg/day or 600 mg/day. The primary outcome measure was the proportion of subjects able to compleate the study with the assigned treatment. Remacemide was generally well tolerated, and no significant differences between the treatment arms were found in the primary outcome measure. A trend toward impovement in chorea was observed among subjects administered remacemide 200 mg/day. Based on the tolerability and safety demonstrated during this short‐trem trial, remacemide warrants more extended controlled investigation in patients with HD.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Huntington's disease</term></item><item><term>Clinical trial</term></item><item><term>Glutamate‐receptor blocker</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1995-10-01">Registration</change><change when="1996-05">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/7D61E5BF3D4506BB687D09C22412B15C5159C9E0/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="30"><doi origin="wiley" registered="yes">10.1002/mds.v11:3</doi><numberingGroup><numbering type="journalVolume" number="11">11</numbering><numbering type="journalIssue">3</numbering></numberingGroup><coverDate startDate="1996-05">May 1996</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="10" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.870110310</doi><idGroup><id type="unit" value="MDS870110310"></id></idGroup><countGroup><count type="pageTotal" number="5"></count></countGroup><titleGroup><title type="articleCategory">Article</title><title type="tocHeading1">Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 1996 Movement Disorder Society</copyright><eventGroup><event type="manuscriptAccepted" date="1995-10-01"></event><event type="firstOnline" date="2004-11-04"></event><event type="publishedOnlineFinalForm" date="2004-11-04"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:HeaderRef result:HeaderRef" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">273</numbering><numbering type="pageLast">277</numbering></numberingGroup><correspondenceTo>University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, U.S.A.</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS870110310.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="3"></count><count type="referenceTotal" number="23"></count></countGroup><titleGroup><title type="main" xml:lang="en">A controlled trial of remacemide hydrochloride in Huntington's disease</title><title type="short" xml:lang="en">REMACEMIDE IN HD</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><honorifics>Dr.</honorifics><givenNames>Karl</givenNames><familyName>Kieburtz</familyName></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Andrew</givenNames><familyName>Feigin</familyName></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Michael</givenNames><familyName>McDermott</familyName></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Peter</givenNames><familyName>Como</familyName></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1"><personName><givenNames>David</givenNames><familyName>Abwender</familyName></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Carol</givenNames><familyName>Zimmerman</familyName></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Charlyne</givenNames><familyName>Hickey</familyName></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Constance</givenNames><familyName>Orme</familyName></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Kathy</givenNames><familyName>Claude</familyName></personName></creator><creator xml:id="au10" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Jennie</givenNames><familyName>Sotack</familyName></personName></creator><creator xml:id="au11" creatorRole="author" affiliationRef="#af1"><personName><givenNames>J. Timothy</givenNames><familyName>Greenamyre</familyName></personName></creator><creator xml:id="au12" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Cynthia</givenNames><familyName>Dunn</familyName></personName></creator><creator xml:id="au13" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Ira</givenNames><familyName>Shoulson</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Fisons Pharmaceuticals, Inc., Rochester, New York, U.S.A.</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Huntington's disease</keyword><keyword xml:id="kwd2">Clinical trial</keyword><keyword xml:id="kwd3">Glutamate‐receptor blocker</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>We conducted a randomized, double‐blind, placebo‐controlled tolerability study of a N‐methyl‐D‐aspartate (NMDA) glutamate receptor ion‐channel blocker, remacemide hydrochloride, in 31 independently ambulatory patients (18 men, 13 women) with Huntington's disease (HD). Subjects were randomized to receive either placebo or active remacemide at dosages of 200 mg/day or 600 mg/day. The primary outcome measure was the proportion of subjects able to compleate the study with the assigned treatment. Remacemide was generally well tolerated, and no significant differences between the treatment arms were found in the primary outcome measure. A trend toward impovement in chorea was observed among subjects administered remacemide 200 mg/day. Based on the tolerability and safety demonstrated during this short‐trem trial, remacemide warrants more extended controlled investigation in patients with HD.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 4-12-2015--><mods version="3.6"><titleInfo lang="en"><title>A controlled trial of remacemide hydrochloride in Huntington's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>REMACEMIDE IN HD</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>A controlled trial of remacemide hydrochloride in Huntington's disease</title></titleInfo><name type="personal"><namePart type="termsOfAddress">Dr.</namePart><namePart type="family">Kieburtz</namePart><affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</affiliation><description>Correspondence: University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, U.S.A.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Andrew</namePart><namePart type="family">Feigin</namePart><affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Michael</namePart><namePart type="family">McDermott</namePart><affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Peter</namePart><namePart type="family">Como</namePart><affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">David</namePart><namePart type="family">Abwender</namePart><affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Carol</namePart><namePart type="family">Zimmerman</namePart><affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Charlyne</namePart><namePart type="family">Hickey</namePart><affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Constance</namePart><namePart type="family">Orme</namePart><affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Kathy</namePart><namePart type="family">Claude</namePart><affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jennie</namePart><namePart type="family">Sotack</namePart><affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J. Timothy</namePart><namePart type="family">Greenamyre</namePart><affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Cynthia</namePart><namePart type="family">Dunn</namePart><affiliation>Fisons Pharmaceuticals, Inc., Rochester, New York, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Ira</namePart><namePart type="family">Shoulson</namePart><affiliation>Department of Neurology and Biostatistics, University of Rochester Medical Center, New York, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">1996-05</dateIssued><dateValid encoding="w3cdtf">1995-10-01</dateValid><copyrightDate encoding="w3cdtf">1996</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">3</extent><extent unit="references">23</extent></physicalDescription><abstract lang="en">We conducted a randomized, double‐blind, placebo‐controlled tolerability study of a N‐methyl‐D‐aspartate (NMDA) glutamate receptor ion‐channel blocker, remacemide hydrochloride, in 31 independently ambulatory patients (18 men, 13 women) with Huntington's disease (HD). Subjects were randomized to receive either placebo or active remacemide at dosages of 200 mg/day or 600 mg/day. The primary outcome measure was the proportion of subjects able to compleate the study with the assigned treatment. Remacemide was generally well tolerated, and no significant differences between the treatment arms were found in the primary outcome measure. A trend toward impovement in chorea was observed among subjects administered remacemide 200 mg/day. Based on the tolerability and safety demonstrated during this short‐trem trial, remacemide warrants more extended controlled investigation in patients with HD.</abstract><subject lang="en"><genre>Keywords</genre><topic>Huntington's disease</topic><topic>Clinical trial</topic><topic>Glutamate‐receptor blocker</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>273</start><end>277</end><total>5</total></extent></part></relatedItem><identifier type="istex">7D61E5BF3D4506BB687D09C22412B15C5159C9E0</identifier><identifier type="DOI">10.1002/mds.870110310</identifier><identifier type="ArticleID">MDS870110310</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 1996 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F54 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 002F54 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:7D61E5BF3D4506BB687D09C22412B15C5159C9E0
|texte= A controlled trial of remacemide hydrochloride in Huntington's disease
}}
| This area was generated with Dilib version V0.6.23. |  |